Maria Pia Sormani, PhD, University of Genoa, Genoa, Italy, describes the project that collected and analyzed data from three thousand patients with multiple sclerosis (MS) that developed COVID-19. From this cohort, two thousand patients were from Italy. Besides the known demographic and clinical risk factors for severe COVID-19 (age, sex, presence of co-morbidities), the study aimed to establish any risk factor associated with MS disease modifying therapies (DMTs). The results from patients receiving anti-CD20 and interferon therapies are discussed. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.